Legalize59765 laws
59765 laws
- § 335. Hearing before report of criminal violation
- § 335a. Debarment, temporary denial of approval, and suspension
- § 335b. Civil penalties
- § 335c. Authority to withdraw approval of abbreviated drug applications
- § 336. Report of minor violations
- § 337. Proceedings in name of United States; provision as to subpoenas
- § 337a. Extraterritorial jurisdiction
- § 341. Definitions and standards for food
- § 342. Adulterated food
- § 347a. Congressional declaration of policy regarding oleomargarine sales
- § 347b. Contravention of State laws
- § 1953. Antidrug program
- § 348. Food additives
- § 349. Bottled drinking water standards; publication in Federal Register
- § 350. Vitamins and minerals
- § 350a. Infant formulas
- § 350a–1. Protecting infants and improving formula supply
- § 350b. New dietary ingredients
- § 350c. Maintenance and inspection of records
- § 350d. Registration of food facilities
- § 350e. Sanitary transportation practices
- § 350f. Reportable food registry
- §§ 21 to 27. Omitted
- § 351. Adulterated drugs and devices
- § 352. Misbranded drugs and devices
- § 353. Exemptions and consideration for certain drugs, devices, and biological products
- § 353a. Pharmacy compounding
- § 353a–1. Enhanced communication
- § 353b. Outsourcing facilities
- § 353c. Prereview of television advertisements
- § 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application
- § 355–1. Risk evaluation and mitigation strategies
- § 356h. Competitive generic therapies
- § 356. Expedited approval of drugs for serious or life-threatening diseases or conditions
- § 356a. Manufacturing changes
- § 356b. Reports of postmarketing studies
- § 356c. Discontinuance or interruption in the production of life-saving drugs
- § 356c–1. Annual reporting on drug shortages
- § 359. Nonapplicability of subchapter to cosmetics
- § 360. Registration of producers of drugs or devices
- § 360a. Clinical trial guidance for antibiotic drugs
- § 360aa. Recommendations for investigations of drugs for rare diseases or conditions
- § 360b. New animal drugs
- § 360bb. Designation of drugs for rare diseases or conditions
- § 360bbb. Expanded access to unapproved therapies and diagnostics
- § 360bbb–0. Expanded access policy required for investigational drugs
- § 360bbb–0a. Investigational drugs for use by eligible patients
- § 360bbb–5. Critical Path Public-Private Partnerships
- § 360bbb–5a. Emerging technology program
- § 360bbb–6. Risk communication